274 In the index

Zopiclone ZOPI

A sleep medication approved for insomnia in many countries (a closely related version, eszopiclone, is sold in the U.S. as Lunesta). Extensive research supports its short-term effectiveness for sleep, along with known risks of next-day grogginess, dependence, and rebound insomnia with prolonged use.

Also known as Imovane, eszopiclone, Amoban, Zimovane, (+-)-Zopiclone, Zopiclona, Zopiclonum, Ximovan

Effects Sleep

Routes Oral

Legal status Controlled substance

WADA Not listed

3D Molecular Structure of C₁₇H₁₇ClN₆O₃

Drag to rotate · scroll to zoom

Chemistry

Formula: C17H17ClN6O3
Molar mass: 388.8
CAS: 43200-80-2
PubChem CID: 5735
IUPAC name: [6-(5-chloro-2-pyridinyl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate
InChIKey: GBBSUAFBMRNDJC-UHFFFAOYSA-N

Reported dosing

Approved label

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose 7.5 mg at bedtime

Reported range 3.75-7.5 mg at bedtime

Route Oral

Frequency Once daily (at bedtime)

Duration Short-term use recommended (per most international labeling), typically no more than 2-4 weeks

Approved for insomnia in many countries (a closely related version, eszopiclone, is sold in the US as Lunesta); not FDA-approved in this exact form in the US. Known risks include next-day grogginess, dependence, and rebound insomnia with prolonged use.

Where this comes from International prescribing information

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.